Investing.com - Unicycive Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Unicycive Therapeutics announced earnings per share of $-0.37 on revenue of $951K. Analysts polled by Investing.com anticipated EPS of $-0.28 on revenue of $0.
Unicycive Therapeutics shares are down 19.03% from the beginning of the year, still down 77.10% from its 52 week high of $3.10 set on November 24, 2021.
Unicycive Therapeutics follows other major Healthcare sector earnings this month
Unicycive Therapeutics's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar